
True-Sciences.com Use Code Pep20 for 20% off. A careful look at CJC-1295: the growth-hormone pathway, the distinction between DAC and no-DAC naming, what small human studies measured, the terminated Phase 2 trial, current FDA compounding information, the unproven CJC-1295/ipamorelin combination claims, and WADA's 2026 rules. The evidence supports a hormone effect for the long-acting DAC-modified compound; it does not establish the benefits often marketed for consumer products. Educational content only; not medical advice. Snapshot checked October 19, 2026.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Can GLP-1 Medications Cause Vision Loss? The New FDA Warning Explained

Kisspeptin: Can It Restart Natural Testosterone Production?

The Secretome Explained: Could Cellular Signaling Transform Medicine?

Monkeys Got Shredded On Peptides?!!
Free AI-powered recaps of Peptides Explained and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.